Zoetis Inc. (ZTS): Price and Financial Metrics
Zoetis Inc. (ZTS)
Today's Latest Price: $157.72 USD
Updated Aug 5 8:04pm
Add ZTS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ZTS Stock Summary
- With a market capitalization of $73,919,781,754, Zoetis Inc has a greater market value than 97.49% of US stocks.
- The price/operating cash flow metric for Zoetis Inc is higher than 90.82% of stocks in our set with a positive cash flow.
- In terms of volatility of its share price, ZTS is more volatile than only 4.41% of stocks we're observing.
- Stocks that are quantitatively similar to ZTS, based on their financial statements, market capitalization, and price volatility, are PKI, GNRC, BDC, IBM, and BDX.
- Visit ZTS's SEC page to see the company's official filings. To visit the company's web site, go to www.zoetis.com.
ZTS Stock Price Chart Technical Analysis Charts
ZTS Price/Volume Stats
| Current price | $157.72 | 52-week high | $158.37 |
| Prev. close | $155.64 | 52-week low | $90.14 |
| Day low | $155.78 | Volume | 1,599,300 |
| Day high | $158.37 | Avg. volume | 2,292,113 |
| 50-day MA | $140.76 | Dividend yield | 0.51% |
| 200-day MA | $130.89 | Market Cap | 74.91B |
Zoetis Inc. (ZTS) Company Bio
Zoetis Inc. discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. The company was founded in 1952 and is based in Florham Park, New Jersey.
ZTS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $157.72 | $79.74 | -49% |
Below please find a table outlining a discounted cash flow forecast for ZTS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Zoetis Inc ranked in the 32th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for ZTS, they are:
- The company has produced more trailing twelve month cash flow than 80.95% of its sector Healthcare.
- The business' balance sheet suggests that 8% of the company's capital is sourced from debt; this is greater than just 20.19% of the free cash flow producing stocks we're observing.
- ZTS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 40.48% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -50% |
| 1% | -49% |
| 2% | -49% |
| 3% | -48% |
| 4% | -48% |
| 5% | -47% |
ENTA, PRAH, ESMC, IONS, and LCI can be thought of as valuation peers to ZTS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...